aciclovir vente acheter metronidazole en ligne strattera 40 mg ditropan prix furosemide prix priligy achat acheter parlodel online naltrexone mg
  • buy aldactone buy metronidazole online generic viagra for sale forum avodart celebrex alcohol interaction norvasc amoxicillin
  • viagra svizzera senza ricetta kamagra pille 100mg cialis generico sicuro cialis mg vente en ligne acquistare viagra sicuro tadalafil en mexico alternative cialis kamagra sicher kaufen levitra generique français
  • cheap generic viagra india lasix mg compresse furosemide albendazole wormer non-prescription cipro order generic cialis onlinelevitra viagra online without prescription aldactone and lisinopril side effects amoxicillin cervical mucus
    wellbutrin comprar online zetia venta libre
    clomid senza ricetta clomid sur internet cialis nederland
    propecia generico 
    viagra kaufen privat 
    costo cialis 5 mg 

    Cancer Prevention Research

    Mon, Nov 25, 2013

    Oral Cancer News


    Clinical and biochemical studies support smokeless tobacco’s carcinogenic potential in the human oral cavity

    Source: American Association of Cancer Research
    Published: November 9, 2013
    By: Susan R. Mallery, Meng Tong, Gregory C. Michaels, Amber R. Kiyani, and Stephen S. Hecht



    In 2007, International Agency for Cancer Research presented compelling evidence that linked smokeless tobacco use to the development of human oral cancer. While these findings imply vigorous local carcinogen metabolism, little is known regarding levels and distribution of Phase I, II and drug egress enzymes in human oral mucosa. In the study presented here, we integrated clinical data, imaging and histopathologic analyses of an oral squamous cell carcinoma that arose at the site of smokeless tobacco quid placement in a patient. Immunoblot and immunohistochemical (IHC) analyses were employed to identify tumor and normal human oral mucosal smokeless tobacco-associated metabolic activation and detoxification enzymes. Human oral epithelium contains every known Phase I enzyme associated with nitrosamine oxidative bioactivation with ~2 fold inter-donor differences in protein levels. Previous studies have confirmed ~3.5 fold inter-donor variations in intraepithelial Phase II enzymes. Unlike the superficially located enzymes in non-replicating esophageal surface epithelium, IHC studies confirmed oral mucosal nitrosamine metabolizing enzymes reside in the basilar and suprabasilar region which notably is the site of ongoing keratinocyte DNA replication. Clearly, variations in product composition, nitrosamine metabolism and exposure duration will modulate clinical outcomes. The data presented here form a coherent picture consistent with the abundant experimental data that links tobacco-specific nitrosamines to human oral cancer.


    * This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.


    Print Friendly
    Be Sociable, Share!
    , , ,

    Leave a Reply

    You must be logged in to post a comment.